CONRAY 30 (iothalamate meglumine) by Guerbet is clinical pharmacology following intravascular injection, conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. First approved in 1971.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
CONRAY 30 is an iodinated contrast agent containing iothalamate meglumine used for radiographic visualization in diagnostic imaging procedures including angiography, CT scanning, and urography. The drug is rapidly excreted unchanged through the kidneys via glomerular filtration, enabling real-time visualization of vascular and organ structures. It works by increasing radiodensity in target tissues, allowing clinicians to visualize anatomical detail during diagnostic procedures.
This legacy product approaching loss of exclusivity is likely supported by a lean, focused team managing mature market share in diagnostic imaging.
CLINICAL PHARMACOLOGY Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The pharmacokinetics of intravascularly administered radiopaque contrast media are usually best…
Worked on CONRAY 30 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CONRAY 30 offers limited growth trajectory but provides stable exposure to diagnostic imaging markets and established healthcare relationships. The approaching LOE phase means team focus will shift toward efficiency, retention, and managed transition rather than revenue expansion.